Klein DE, Bullen M, Zhu DT, Kesselheim AS - Annals of Internal Medicine
The Drug Enforcement Agency’s (DEA) new rule requiring in-person visits after six months of telehealth-initiated buprenorphine treatment lacks clinical or public health justification and could disrupt care for patients with opioid use disorder. The authors contend that the rule’s seven exceptions are largely impractical for outpatient addiction settings and urge for the removal of the arbitrary time limit.
VIEW SOURCE
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open